Skip to main content
SpringerLink
Log in
Book cover

Side Effects of Medical Cancer Therapy pp 249–266Cite as

Myeloid Malignancies

  • Chapter
  • First Online:

  • 970 Accesses

Abstract

Myeloid malignancies comprise the various myeloid proliferative stem cell disorders. In this chapter, the side effects of the currently used drugs are given as used in the general hematologic clinic. For the various disorders covered, the side effects of the medications are pleomorphic; therefore, for the tyrosine kinase inhibitors in chronic myeloid leukemia, a tabulated summary is given. Hematopoietic stem cells, autologous as well as allogeneic, are not covered. These treatment modalities are used in very specialized units, and the patient’s follow-up during the first few months is also done through these units, which are very familiar with the therapies.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Chabner B, Wilson W, Supko J. Pharmacology and toxicity of antineoplastic drugs. In:Williams haematology. 7th ed. New York: McGraw-Hill; 2006. p. 249–74.

    Google Scholar 

  2. Fernandez H. New trends in the standard of care for initial therapy. Hematology Am Soc Hematol Educ Program. 2010;2010:56–61.

    PubMed  Google Scholar 

  3. Fenaux P, Gattermann N, Seymour JF, Hellström-Lindberg E, Mufti GJ, Duehrsen U, et al. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. Br J Haematol. 2010;149(2):244–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Santini V, Fenaux P, Mufti GJ, Hellström-Lindberg E, Silverman LR, List A, et al. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine. Eur J Haematol. 2010;85(2):130–8.

    PubMed  PubMed Central  CAS  Google Scholar 

  5. Almeida AM, Pierdomenico F. Generalized skin reactions in patients with MDS and CMML treated with azacitidine: effective management with concomitant prednisolone. Leuk Res. 2012;36(9):e211–3.

    Article  PubMed  Google Scholar 

  6. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Lazarus HM, Herzig RH, Herzig GP, Phillips GL, Roessmann U, Fishman DJ. Central nervous system toxicity of high-dose systemic cytosine arabinoside. Cancer. 1981;48(12):2577–82.

    Article  CAS  PubMed  Google Scholar 

  9. Johnson H, Smith TJ, Desforges J. Cytosine-arabinoside-induced colitis and peritonitis: nonoperative management. J Clin Oncol. 1985;3(5):607–12.

    Article  CAS  PubMed  Google Scholar 

  10. Löwenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011;364(11):1027–36.

    Article  PubMed  Google Scholar 

  11. Mandelli F, Vignetti M, Suciu S, Stasi R, Stasi R, Petti MC, Meloni G, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol. 2009;27(32):5397–403.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Moreb JS, Oblon DJ. Outcome of clinical congestive heart failure induced by anthracycline chemotherapy. Cancer. 1992;70:2637.

    Article  CAS  PubMed  Google Scholar 

  13. Leoni F, Ciolli S, Nozzoli C, Marrani C, Caporale R, Ferrini PR. Idarubicin in induction treatment of acute myeloid leukemia in the elderly. Haematologica. 1997;82(5 Suppl):13–8.

    PubMed  CAS  Google Scholar 

  14. Legha SS, Keating MJ, McCredie KB, Bodey GP, Freireich EJ. Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults. Blood. 1982;60(2):484–90.

    PubMed  CAS  Google Scholar 

  15. Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, et al. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I trial. J Clin Oncol. 2012;30(20):2492–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Claxton D, Erba HP, Faderl S, Arellano M, Lyons RM, Kovacsovics T, et al. Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia. Leuk Lymphoma. 2012;53(3):435–40.

    Article  CAS  PubMed  Google Scholar 

  17. Kantarjian HM, Erba HP, Claxton D, Arellano M, Lyons RM, Kovascovics T, et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol. 2010;28(4):549–55.

    Article  CAS  PubMed  Google Scholar 

  18. Candoni A, Martinelli G, Toffoletti E, Chiarvesio A, Tiribelli M, Malagola M, et al. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years. Leuk Res. 2008;32(12):1800–8.

    Article  CAS  PubMed  Google Scholar 

  19. de Lima M, Champlin RE, Thall PF, Wang X, Martin TG, Cook JD, et al. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia. 2008;22(2):258–64.

    Article  CAS  PubMed  Google Scholar 

  20. Baz W, Najfeld V, Yotsuya M, Talwar J, Terjanian T, Forte F. Development of myelodysplastic syndrome and acute myeloid leukemia 15 years after hydroxyurea use in a patient with sickle cell anemia. Clin Med Insights Oncol. 2012;6:149–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Antonioli E, Guglielmelli P, Pieri L, Finazzi M, Rumi E, Martinelli V, et al. Hydroxyurea-related toxicity in 3,411 patients with Ph’-negative MPN. Am J Hematol. 2012;87(5):552–4. https://doi.org/10.1002/ajh.23160.

    Article  PubMed  Google Scholar 

  22. Kluger N, Naud M, Françès P. Toenails melanonychia induced by hydroxyurea. Presse Med. 2012;41(4):444–5.

    Article  PubMed  Google Scholar 

  23. Gugliotta L, Tieghi A, Tortorella G, Scalzulli PR, Ciancia R, Lunghi M, et al. Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia. Leuk Res. 2011;35(12):1557–63.

    Article  CAS  PubMed  Google Scholar 

  24. Birgegård G, Björkholm M, Kutti J, Lärfars G, Löfvenberg E, Markevärn B, et al. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Haematologica. 2004;89(5):520–7.

    PubMed  Google Scholar 

  25. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251–9.

    Article  CAS  PubMed  Google Scholar 

  26. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260–70.

    Article  CAS  PubMed  Google Scholar 

  27. Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015;33(35):4210–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Cervantes F, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Sirulnik A, Stalbovskaya V, McQuitty M, Hunter DS, Levy RS, Passamonti F, Barbui T, Barosi G, Harrison CN, Knoops L, Gisslinger H, COMFORT-II Investigators. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122(25):4047–53.

    Article  CAS  PubMed  Google Scholar 

  29. Kirito K, Sakamoto M, Enomoto N. Elevation of the hepatitis B virus DNA during the treatment of polycythemia vera with the JAK kinase inhibitor ruxolitinib. Intern Med. 2016;55(10):1341–4.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg

    Laurent Plawny

Authors
  1. Laurent Plawny
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laurent Plawny .

Editor information

Editors and Affiliations

  1. Department of Hematology-Oncology, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg

    Mario A. Dicato

  2. Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium

    Eric Van Cutsem

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Plawny, L. (2018). Myeloid Malignancies. In: Dicato, M., Van Cutsem, E. (eds) Side Effects of Medical Cancer Therapy. Springer, Cham. https://doi.org/10.1007/978-3-319-70253-7_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-70253-7_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-70252-0

  • Online ISBN: 978-3-319-70253-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation